|
|
 Canadian
Medical Association Journal
Home |
|
Nefazodone HCL (Serzone-5HT2; LinNefazodone) (June 27, 2001) Nefazodone, used in the management of depressive illnesses, has been associated with 109 serious adverse events, including some deaths. Reports of severe hepatic injury and liver failure leading to transplantation and causing death have been reported. The onset of liver damage is usually seen within 4 months of initiating treatment, but can occur after continuous use for longer periods. Physicians should warn patients of the dangers associated with this medication and report adverse events to Health Canada.CMAJ
Copyright 2001 Canadian Medical Association or its licensors |
